Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer

BACKGROUND: The FDA recently approved an anti-CTLA-4 antibody (Iplimumab) for the treatment of metastatic melanoma. This decision was based on Phase III results, which demonstrate that blocking this immune checkpoint provides a survival advantage in patients with advanced disease. As a single agent,...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Wada, Satoshi, Jackson, Christopher M, Yoshimura, Kiyoshi, Yen, Hung-Rong, Getnet, Derese, Harris, Timothy J, Goldberg, Monica V, Bruno, Tullia C, Grosso, Joseph F, Durham, Nicholas, Netto, George J, Pardoll, Drew M, Drake, Charles G
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2013
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC3666941/
https://ncbi.nlm.nih.gov/pubmed/23557194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-89
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים